|
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical research trials and Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer  Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
For Condition: Adenocarcinoma,Stomach Neoplasms
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - No prior chemotherapy for locally advanced or metastatic disease - Adequate baseline bone marrow, hepatic and renal function - Age >= 18 years - At least one target lesion Exclusion Criteria: - Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse) - Symptomatic brain metastases which are not stable
Total Enrollment: 43
Location and Contact Information:
Cookridge Hospital *Recruiting*
Leeds, , LS16 6BB
United Kingdom
Recruiting OSIP Information (800) 572-1932
University of Utah, Huntsman Cancer Institute *Not yet recruiting*
Salt Lake City, Utah, 84112
United States
Not yet recruiting OSIP Information 800-572-1932
Christie Hospital NHS Trust *Recruiting*
Manchester, , M20 4BX
United Kingdom
Recruiting OSIP Information (800) 572-1932
New Cross Hospital *Recruiting*
Wolverhampton, , WV10 0QP
United Kingdom
Recruiting OSIP Information (800) 572-1932
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting OSIP Information 800-572-1932
Churchill Hospital *Recruiting*
Headington, Oxford, OX3 7LJ
United Kingdom
Recruiting OSIP Information (800) 572-1932
University of Pennsylvania Cancer Center *Not yet recruiting*
Philadelphia, Pennsylvania, 19104
United States
Not yet recruiting OSIP Information 800-572-1932
Dept Internal Medicine Gastrointestinal Oncology Unit *Not yet recruiting*
B-3000 Leuven, ,
Belgium
Not yet recruiting OSIP Information (800) 572-1932
Belfast City Hospital *Not yet recruiting*
Belfast, , BT9 7AB
United Kingdom
Not yet recruiting OSIP Information (800) 572-1932
University of Glasgow *Recruiting*
Glasgow, , G11 6NT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Bristol Haematology & Oncology Centre *Recruiting*
Bristol, Avon, BS2 8ED
United Kingdom
Recruiting OSIP Information (800) 572-1932
Additional Information:
Study ID Numbers: OSI-904-201;
Study Start Date: October 2003
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073502
Other Adenocarcinoma Studies:
1. A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery
2. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
3. Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis
4. Tezacitabine with or without 5-Fluorouracil (5-FU) for advanced esophageal cancer or gastric cancer
5. A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Related Studies:
Other Adenocarcinoma Clinical Trials
Other Utah Clinical Trials
Other Salt Lake City Clinical Trials
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
|
|
|
|
|
|
|
|
